Funding: N. G. S. gratefully acknowledges funding support from the National Health and Medical Research Council of Australia and the Motor Neuron Disease Research Institute of Australia.
Common peroneal neuropathy and cancer
Article first published online: 18 JUL 2012
© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians
Internal Medicine Journal
Volume 42, Issue 7, pages 837–840, July 2012
How to Cite
Simon, N. G. and Kiernan, M. C. (2012), Common peroneal neuropathy and cancer. Internal Medicine Journal, 42: 837–840. doi: 10.1111/j.1445-5994.2012.02836.x
Conflict of interest: None.
- Issue published online: 18 JUL 2012
- Article first published online: 18 JUL 2012
- Received 8 July 2011; accepted 22 October 2011.
- peroneal neuropathy;
Common peroneal neuropathy (CPN) may develop unexpectedly in patients with underlying cancer. To clarify the underlying pathophysiology, clinical and neurophysiological data were prospectively collected from 10 oncology clinic patients referred for neurological assessment after the onset of foot weakness. In all patients, the CPN occurred in the setting of advanced systemic malignancy frequently associated with marked weight loss at the time of foot weakness. Neurophysiological studies localised the CPN to the fibular head in 80% of cases. Findings from this study, combined with recent experimental evidence, support the hypothesis that clinically evident CPN develops after rapid weight loss, perhaps reflecting a relative metabolic deficiency within the nerve, which exposes anatomical susceptibility and possible subclinical pre-existing nerve injury.